SCHEMBL3370064

SCHEMBL3370064

Cc1cccc(N(c2ccc(C=Cc3ccc(N(c4cccc(C)c4)c4cccc(C)c4)cc3)cc2)c2cccc(C)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RELA Q04206 2/20 0.47
APP P05067 7/20 0.42
NFE2L2 Q16236 2/20 0.42
ACHE P22303 1/20 0.41
PTGS1 P23219 2/20 0.41
ALOX5 P09917 1/20 0.41
PTGS2 P35354 1/20 0.41
MAT2A P31153 1/20 0.40
KCNH2 Q12809 1/20 0.40
TP53 P04637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
INSR P06213 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
NPC1 O15118 1/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13992026 1.00 RELA (0.47) RELAAPPNFE2L2ACHEPTGS1
SCHEMBL30151497 1.00 RELA (0.47) RELAAPPNFE2L2ACHEPTGS1
SCHEMBL13992003 1.00 RELA (0.47) RELAAPPNFE2L2ACHEPTGS1
SCHEMBL4260913 1.00 RELA (0.47) RELAAPPNFE2L2ACHEPTGS1
SCHEMBL12148768 1.00 RELA (0.47) RELAAPPNFE2L2ACHEPTGS1
SCHEMBL4260910 1.00 RELA (0.47) RELAAPPNFE2L2ACHEPTGS1
SCHEMBL24041888 0.96 NFE2L2 (0.47) RELAAPPNFE2L2PTGS1ALOX5
SCHEMBL7717148 0.96 RELA (0.48) RELAAPPNFE2L2ACHEPTGS1
SCHEMBL10128949 0.96 RELA (0.48) RELAAPPNFE2L2ACHEPTGS1
SCHEMBL21168151 0.96 NFE2L2 (0.47) RELAAPPNFE2L2PTGS1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1496044-B1 NOVEL 1,3,5-TRIS(ARYLAMINO)BENZENE BANDO CHEMICAL IND (JP) 2010-11-03 EP disclosed
US-7271291-B2 1,3,5-tris (arylamino) benzenes BANDO CHEMICAL INDUSTRIES, LTD. (JP) 2007-09-18 US disclosed
US-7196224-B2 1,3,5-tris(arylamino)benzenes BANDO CHEMICAL INDUSTRIES, LTD. (JP) 2007-03-27 US disclosed
US-20060173216-A1 Novel 1, 3, 5 tris (arylamino) benzenes BANDO CHEMICAL INDUSTRIES, LTD. (JP) 2006-08-03 US disclosed
US-20050090692-A1 Novel 1,3,5-tris(arylamino)benzene BANDO CHEMICAL INDUSTRIES, LTD. (JP) 2005-04-28 US disclosed
EP-1496044-A1 NOVEL 1,3,5-TRIS(ARYLAMINO)BENZENE Bando Chemical Industries, Ltd. (JP) 2005-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173216-A1 Novel 1, 3, 5 tris (arylamino) benzenes HSPA4L, HSPA1A, GAPVD1 RELA 2141/4885APP 1938/4885NFE2L2 732/4885
US-20050090692-A1 Novel 1,3,5-tris(arylamino)benzene AHR, MYB, NAP1L4 RELA 1523/4885APP 1416/4885NFE2L2 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.